207 related articles for article (PubMed ID: 20409289)
1. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients.
Tostmann A; van den Boogaard J; Semvua H; Kisonga R; Kibiki GS; Aarnoutse RE; Boeree MJ
Trop Med Int Health; 2010 Feb; 15(2):268-72. PubMed ID: 20409289
[TBL] [Abstract][Full Text] [Related]
2. Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi.
Tostmann A; Boeree MJ; Harries AD; Sauvageot D; Banda HT; Zijlstra EE
Trop Med Int Health; 2007 Jul; 12(7):852-5. PubMed ID: 17596252
[TBL] [Abstract][Full Text] [Related]
3. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis.
Lomtadze N; Kupreishvili L; Salakaia A; Vashakidze S; Sharvadze L; Kempker RR; Magee MJ; del Rio C; Blumberg HM
PLoS One; 2013; 8(12):e83892. PubMed ID: 24367617
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus.
Mo P; Zhu Q; Teter C; Yang R; Deng L; Yan Y; Chen J; Zeng J; Gui XE
Int J Infect Dis; 2014 Nov; 28():95-100. PubMed ID: 25218771
[TBL] [Abstract][Full Text] [Related]
6. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
[TBL] [Abstract][Full Text] [Related]
7. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity to different antituberculosis drug combinations.
Aziz S; Agha F; Hassan R; Fairoz SA; Hassan K
J Pak Med Assoc; 1990 Dec; 40(12):290-4. PubMed ID: 2126569
[TBL] [Abstract][Full Text] [Related]
9. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment.
Chien JY; Huang RM; Wang JY; Ruan SY; Chien YJ; Yu CJ; Yang PC
Int J Tuberc Lung Dis; 2010 May; 14(5):616-21. PubMed ID: 20392356
[TBL] [Abstract][Full Text] [Related]
11. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
12. Antituberculous drug-induced liver injury: current perspective.
Devarbhavi H
Trop Gastroenterol; 2011; 32(3):167-74. PubMed ID: 22332331
[TBL] [Abstract][Full Text] [Related]
13. [The impact of antituberculosis drugs upon liver function in patients with positive HBVM].
Chen GQ
Zhonghua Jie He He Hu Xi Za Zhi; 1989 Apr; 12(2):89-90, 126. PubMed ID: 2791129
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis.
Pore SM; Shinde K
J Postgrad Med; 2014; 60(1):90-2. PubMed ID: 24625953
[No Abstract] [Full Text] [Related]
16. Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.
Saha A; Shanthi F X M; Winston A B; Das S; Kumar A; Michael JS; Balamugesh T
J Prim Care Community Health; 2016 Jul; 7(3):171-4. PubMed ID: 27056794
[TBL] [Abstract][Full Text] [Related]
17. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.
Shakya R; Rao BS; Shrestha B
Ann Pharmacother; 2004 Jun; 38(6):1074-9. PubMed ID: 15122004
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis.
Lima Mde F; Melo HR
Cad Saude Publica; 2012 Apr; 28(4):698-708. PubMed ID: 22488315
[TBL] [Abstract][Full Text] [Related]
19. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function.
Padmapriyadarsini C; Chandrabose J; Victor L; Hanna LE; Arunkumar N; Swaminathan S
J Postgrad Med; 2006; 52(2):92-6. PubMed ID: 16679670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
